Thrombomodulin protects against lung damage created by high level of oxygen with large tidal volume mechanical ventilation in rats by unknown
Iwashita et al. Journal of Intensive Care 2014, 2:57
http://www.jintensivecare.com/content/2/1/57RESEARCH Open AccessThrombomodulin protects against lung damage
created by high level of oxygen with large tidal
volume mechanical ventilation in rats
Yoshiaki Iwashita1,3†, Erquan Zhang1†, Junko Maruyama1,4, Ayumu Yokochi1, Yasuharu Yamada1,4, Hirofumi Sawada1,2,
Yoshihide Mitani2, Hiroshi Imai3, Koji Suzuki5 and Kazuo Maruyama1*Abstract
Background: Ventilator-induced lung injury (VILI) is associated with inflammatory responses in the lung.
Thrombomodulin (TM), a component of the coagulation system, has anticoagulant and anti-inflammatory effects.
We hypothesized that the administration of recombinant human soluble TM (rhsTM) would block the development
of lung injury.
Methods: Lung injury was induced by high tidal volume ventilation for 2 h with 100% oxygen in rats. Rats were
ventilated with a tidal volume of 35 ml/kg with pretreatment via a subcutaneous injection of 3 mg/kg rhsTM (HV
(high tidal volume)/TM) or saline (HV/SAL) 12 h before mechanical ventilation. Rats ventilated with a tidal volume of
6 ml/kg under 100% oxygen with rhsTM (LV (low tidal volume)/TM) or saline (LV/SAL) were used as controls. Lung
protein permeability was determined by Evans blue dye (EBD) extravasation.
Results: Lung injury was successfully induced in the HV/SAL group compared with the LV/SAL group, as shown
by the significant decrease in arterial oxygen pressure (PaO2), increased protein permeability, and increase in
mean pulmonary artery pressure (mPAP) and ratio of mean pulmonary artery pressure to mean artery pressure
(Pp/Ps). Treatment of rats with lung injury with rhsTM (HV/TM) significantly attenuated the decrease in PaO2 and
the increase in both mPAP and Pp/Ps, which was associated with a decrease in the lung protein permeability. Lung
tissue mRNA expressions of interleukin (IL)-1α, IL-1β, IL-6, tumor necrosis factor-α, and macrophage inflammatory
protein (MIP)-2 were significantly higher in HV than in LV rats. Rats with VILI treated with rhsTM (HV/TM) had
significantly lower mRNA expressions of IL-1α, IL-1β, IL-6, and MIP-2 than those expressions in HV/SAL rats.
Conclusions: Administration of rhsTM may prevent the development of lung injury created by high level of oxygen
with large tidal volume mechanical ventilation, which has concomitant decrease in proinflammatory cytokine and
chemokine expression in the lung.
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Mechanical ventilation can initiate or exacerbate lung
injury, causing what is referred to as ventilator-induced
lung injury (VILI) [1]. A high transalveolar pressure, tidal
volume, and respiratory rate contribute to the development
of VILI [2]. Mechanical force not only causes disruption of* Correspondence: k-maru@clin.medic.mie-u.ac.jp
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unless otherwise stated.the lung tissue but also induces biochemical changes in the
lung, leading to an upregulation of inflammatory responses,
such as increased neutrophil infiltration and inflammatory
mediators in bronchoalveolar lavage fluid and the lung
tissue [3,4]. Minimizing alveolar overdistension with a
low tidal volume attenuates inflammatory changes in
VILI [5] and improves the mortality of acute respiratory
distress syndrome (ARDS) patients [6] and abdominal
surgical patients under general anesthesia [7]. In an
animal model of VILI, mechanical ventilation caused a
procoagulant and anti-fibrinolytic state, so-called ventilator-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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thrombin-antithrombin complex and plasminogen activator
inhibitor-1 [8,9].
Thrombomodulin (TM) is a transmembrane glycoprotein
receptor for thrombin that has anticoagulant and anti-
inflammatory effects [10-12]. Thrombin converts fibrinogen
to fibrin. Binding of fibrin to monocytes activates nuclear
factor kappa B (NF-κB), which activates proinflamma-
tory cytokine production [9,13]. Thrombin also activates
protease-activated receptors (PARs) on the cell surface and
subsequently stimulates the production of adhesion mole-
cules in endothelium and leukocytes [14] and interleukin
(IL)-6 and IL-8 in endothelial cells [15], thereby potentiat-
ing leukocyte chemotaxis and adhesion. These effects of
thrombin are associated with VILI, with an earlier study
showing an increase in intracellular adhesion molecules
in macrophages obtained by the lung lavage from rats
with VILI [3].
Binding of TM to thrombin to assemble the thrombin-
TM complex has the following effects: (1) activation of
protein C to form activated-protein C (APC) which inhibits
factors Va and VIIIa and suppresses further thrombin
formation; (2) sequestration of thrombin, thereby reducing
fibrin formation; (3) formation of thrombin-activatable
fibrinolysis inhibitor and subsequent C5a inactivation;
and (4) inhibition of high-mobility group box 1 (HMGB-
1), a late mediator of sepsis [11,16]. These effects of TM
antagonize thrombin’s procoagulant and proinflammatory
activity, which are exerted via the TM expressed on vascu-
lar endothelial cells [10-12].
Recently, recombinant human soluble TM (rhsTM) was
approved for the treatment of disseminated intravascular
coagulopathy (DIC) in Japan [12]. Patients with sepsis asso-
ciated with DIC tend to receive mechanical ventilation
under oxygen inhalation at high concentrations. Because we
hypothesized that administration of an exogenous TM such
as rhsTM would prevent the development of lung injury,
the purpose of this study was to determine if rhsTM admin-
istration ameliorates lung injury created by high level of
oxygen with large-tidal volume mechanical ventilation in rats.
Methods
Animals
Male Sprague-Dawley rats (Clea, Japan) weighing 250–350
g were used. The animal experiments committee of the
Mie University School of Medicine, Mie, Japan approved
the study protocol.
Preliminary experiment
In a preliminary experiment performed to select the
experimental condition for induction of VILI in rats, 29
rats were assigned to one of the seven groups and
ventilated under the following tidal volume conditions:
(1) 6 ml/kg under room air (low tidal volume (LV) 6),(2) 20 ml/kg under room air (HV20), (3) 30 ml/kg
under room air (HV30), (4) 35 ml/kg under room air
(HV35), (5) 40 ml/kg under room air (HV40), (6) 35
ml/kg under 100% oxygen inhalation (HV35O2), and
(7) 40 ml/kg under 100% oxygen inhalation (HV40O2).
After mechanical ventilation for 2 h with the assigned
tidal volume, Evans blue dye (EBD) extravasation was
measured as an index of lung protein permeability.
EBD strongly binds to albumin and is used as a marker
of protein extravasation in lung injury models [9,17,18].
Based on these results (Figure 1), we decided to induce
lung injury via a tidal volume of 35 ml/kg under 100%
oxygen inhalation.
Mechanical ventilation
A tracheostomy was performed under intraperitoneal
pentobarbital (45 mg/kg) anesthesia and a plastic cannula
(SP-110; Natsume, Tokyo, Japan) was inserted into the
trachea. The rats were then ventilated using an SN-480-7
volume cycle ventilator (Shinano Co., Nagoya City, Japan).
Muscle relaxation was achieved using pancuronium
bromide (0.1 mg/kg). Positive end-expiratory pressure
was not applied. To maintain arterial carbon dioxide
tension at a pressure between 40–50 mmHg, the respira-
tory rate was adjusted to be 30–100 breaths/min, and the
dead space was adjusted by inserting a tube between the
Y-piece of the ventilator circuit and tracheostomy cannula
in the high tidal volume group.
Experimental group
Twenty rats were divided into four groups as follows: (1)
rats pretreated with saline and ventilated with a tidal
volume of 6 ml/kg under 100% oxygen inhalation (LV/
saline (SAL)) (n = 5); (2) rats pretreated with rhsTM and
ventilated with a tidal volume of 6 ml/kg under 100%
oxygen inhalation (LV/TM) (n = 5); (3) rats pretreated
with saline and ventilated with a tidal volume of 35 ml/
kg under 100% oxygen inhalation (HV/SAL) (n = 5); and
(4) rats pretreated with rhsTM and ventilated with a
tidal volume of 35 ml/kg under 100% oxygen inhalation
(HV/TM) (n = 5). The rats were subcutaneously injected
with 3 mg/kg of rhsTM (Asahi Kasei Pharma, Tokyo,
Japan) dissolved in saline or saline alone 12 h before the
start of the mechanical ventilation. In a previous study,
we showed that plasma rhsTM levels were elevated after
9 h and remained elevated for 48 h after subcutaneous
rhsTM injection [19].
Catheterization
The left internal carotid artery was cannulated for meas-
uring artery pressure and sampling for arterial blood gas
analysis. A pulmonary artery catheter (Silastic tubing,
0.31 mm inner diameter and 0.64 mm outer diameter)
was inserted via the right external jugular vein into the
Figure 1 Preliminary experiment: Evans blue dye (EBD) extravasation as an estimate of lung protein permeability for different tidal
volumes, with and without 100% oxygen inhalation. LV6, rats ventilated under room air with a tidal volume of 6 ml/kg; HV20, HV30, HV35,
HV40, rats ventilated under room air with tidal volumes of 20, 30, 35, and 40 ml/kg, respectively; HV35O2 and HV40O2, rats ventilated with tidal
volumes of 35 and 40 ml/kg under 100% oxygen inhalation, respectively. Bars indicate mean ± SE. *P < 0.05 versus the LV6 group. n = number of
rats treated with mechanical ventilation.
Iwashita et al. Journal of Intensive Care 2014, 2:57 Page 3 of 10
http://www.jintensivecare.com/content/2/1/57pulmonary artery using the closed-chest technique, as
previously described [19,20]. Airway pressure was measured
at the tracheostomy cannula. Mean artery pressure (mAP),
mean pulmonary artery pressures (mPAP), and airway
pressure were recorded with a physiological transducer
and amplifier system (AP 620; Nihon Kohden, Tokyo,
Japan). The ratio of mPAP to mAP (Pp/Ps) was calculated
as an estimate of pulmonary hypertension.
Experimental protocol
All rats were initially ventilated with a tidal volume of
6 ml/kg. After a 15-min stabilization, an intravenous
injection of 30 mg/kg EBD was given. Baseline arterial
blood gas analysis was performed before the assignment
of experimental tidal volume. After a 30-min stabilization,
a tidal volume of 6 or 35 ml/kg was assigned, and
mechanical ventilation was continued for another 2 h.
Further arterial blood samples were obtained every 30 min
after the assignment of a tidal volume and were analyzed
by a portable blood gas analyzer (iSTAT Analyzer 200;
Abbott Point Care Inc., Princeton, NJ, USA). Alveolar-
arterial oxygen difference (A-aDO2) was calculated with
the following formula: A-aDO2 = (760 − 47) × 1.0 − PaCO2/
0.8 − PaO2 = 713 – PaCO2/0.8 − PaO2. At the end of the
protocol, the lung tissue was obtained to measure the lung
water content and pulmonary microvascular permeability.
EBD extravasation and the lung dry/wet weight ratio
EBD extravasation into the lung as an estimate of pro-
tein permeability was quantitated as previously described
[17,18]. After thoracotomy, the upper lobe of the rightlung was ligated and harvested to determine the lung
water content. The rest of the lung was perfused via the
pulmonary artery for 2 min with saline to eliminate
residual blood and EBD from the pulmonary bed [18].
After perfusion, the left lung was excised, rinsed externally
with saline, and then placed in a drying oven at 90°C for
24 h. Dried tissue samples were placed in 2 ml formamide
at 37°C for 24 h. The EBD concentration was measured by
dual wavelength spectrophotometry at 620 and 740 nm,
which allows for the correction of contaminating heme
pigments. The corrected absorbance at 620 nm was
calculated using the following formula: Corrected absorb-
ance at 620 mm= actual absorbance at 620 mm − [1.426
(absorbance at 740 mm) − 0.03]. The total amount of EBD
in the dried lung sample was calculated, and EBD extra-
vasation was expressed as micrograms per gram of the
dried lung tissue sample. The upper lobe of the right
lung was placed in a drying oven at 90°C for 24 h. The
lung dry-to-wet weight (dry/wet) ratio as an estimate of
lung water content was determined by the following
formula: (wet lung weight – dried lung weight)/wet lung
weight × 100 (%).
cDNA preparation and real-time polymerase chain reaction
In another set of experiments with 21 rats [(LV/SAL)
(n = 5), LV/TM (n = 5), HV/SAL (n = 6), and HV/TM
(n = 5)], the lung samples were obtained for real-time
polymerase chain reaction (PCR) and Western blotting.
Interleukin (IL)-1α, IL-1β, IL-6, tumor necrosis factor-α
(TNFα), macrophage inflammatory protein (MIP)-2, rho-
associated kinase (ROCK)-1, and HMGB-1 mRNA levels
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of total RNA from whole lung tissue [LV/SAL (n = 5),
LV/TM (n = 5), HV/SAL (n = 6), HV/TM (n = 5)] using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), cDNA
synthesis was performed with ReverTra Ace (Toyobo
Co., Ltd., Biochemical Operations Department, Osaka,
Japan). Amplification was performed with a StepOne Plus
Real Time PCR System (Applied Biosystems, Thermo
Fisher Scientific, Waltham, MA, USA). The sequences of
the primer pairs are listed in Table 1. Relative quantifica-
tion was performed with the comparative ΔΔCt method
by normalization with β-actin mRNA.
Western blotting
Western blotting for ROCK-1 and HMGB-1 in whole
lung tissue was performed as described previously [19].
Three kinds of primary antibodies (anti-HMGB-1, 1:5,000,
#3935S, (Cell Signaling Technology, Danvers, MA, USA);
anti-ROCK-1, 1:5,000 dilution, 611136, (BD Transduction
Laboratories, San Jose, CA, USA); anti-β-actin, 1:200,000
dilution, A5441 (Sigma-Aldrich, St. Louis, MO, USA))
were incubated at 4°C overnight. Secondary antibodies
(anti-mouse IgG-HRP, 1:20,000 dilution, NA 931,
Amersham; anti-rabbit IgG-HRP, 1:20,000 dilution,
D2313, Santa Cruz Biotechnology, Dallas, TX, USA)
were incubated for 1 h at room temperature.
Data analysis
Values are expressed as mean ± SE. When more than
two means were compared, one-way analysis of variance
was used. When significant variance was found, Fisher’s
predicted least significant difference test was used toTable 1 Primer list
















R: TAG TTTCATGGATGCCACAGGATestablish which groups were different. P < 0.05 was con-
sidered to be significant.
Results
Preliminary experiment: effect of tidal volume and 100%
oxygen inhalation
In a preliminary experiment, we evaluated the conditions
required to induce experimental lung injury in rats. EBD
extravasation increased with escalation in tidal volume but
did not reach significant difference in room air, probably
because of the relatively small number of samples. Under
100% O2 inhalation, EBD extravasation was significantly
increased in the HV35O2 and HV40O2 groups compared
with the LV6 group (Figure 1). There was no significant
difference between the LV6 group and the HV20, HV30,
HV35, or HV40 groups. Overall, the results suggested that
a high tidal volume with 100% oxygen tended to cause
high EBD extravasation, an estimate of the lung protein
permeability. We wanted to select the specific condition
for obtaining a stable lung injury model in an experimen-
tal setting. Two out of four rats in the HV40 and HV40O2
groups became unstable and died so we decided to induce
lung injury in rats by ventilating with 35 ml/kg and 100%
oxygen in subsequent experiments in which the protective
effects of TM for the development of VILI were deter-
mined. Several other studies also induced lung injury
under 100% oxygen inhalation [2,21,22]. An earlier study
showed that ventilation with 35 ml/kg tidal volume for
156 min compromise systemic circulation, leading to
shock [23], in which ventilation time is longer than our
study (2 h).
Arterial oxygen pressure, A-aDO2, EBD extravasation, and
the lung dry/wet weight ratio
PaO2 was significantly decreased in the HV/SAL group
compared with the LV/SAL group at 1, 1.5, and 2 h after
the start of mechanical ventilation. The decrease in
PaO2 was significantly attenuated in the HV/TM group
compared with the HV/SAL group at 1 and 2 h. There
was no difference in PaO2 between the HV/TM and LV
groups. Thus, the decrease in PaO2 with high tidal
ventilation was prevented by TM treatment (Figure 2A).
These results were confirmed with A-aDO2, an estimate
of oxygenation that excludes the effect of alveolar carbon
dioxide. EBD extravasation, a marker of protein perme-
ability, was significantly increased in the HV/SAL group
and HV/TM group compared with the LV/SAL group
and LV/TM group, respectively (Figure 2C). Although not
significant, the lung dry/wet ratio tended to be increased
in the HV/SAL group and HV/TM group compared
with the LV/SAL group and LV/TM group, respectively
(Figure 2D). The increase in EBD extravasation and the
lung dry/wet weight ratio was lower in HV/TM rats
than in HV/SAL rats (Figure 2C, D) but did not reach
Figure 2 Arterial oxygen pressure, A-aDO2, Evans blue dye (EBD) extravasation, and the lung dry/wet weight ratio. (A) Arterial oxygen
pressure (PaO2), (B) alveolar-arterial oxygen difference (A-aDO2), (C) EBD extravasation, an estimate of protein permeability, (D) the lung dry-to-wet
(dry/wet) weight ratio, an estimate of the lung water content. LV low tidal volume (6 ml/kg), HV high tidal volume (35 ml/kg), SAL saline, TM
thrombomodulin. 0 h, baseline measurement (tidal volume of 6 ml/kg) before the assignment of experimental tidal volume; 0.5, 1, 1.5, and
2 h, hours after the assignment of experimental tidal volume (6 ml/kg or 35 ml/kg). Bars indicate mean ± SE. *P < 0.05 versus the respective LV
groups. #P < 0.05 versus the HV/SAL group. n = number of rats.
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animals. Overall, these results showed that the HV/TM
group had less lung injury, as measured by three independ-
ent methods, than the HV/SAL (positive control) group,
suggesting that TM administration might ameliorate lung
injury associated with high tidal volume ventilation.
mPAP and Pp/Ps
Because pulmonary artery pressure increases in severe
lung injury [24], we measured mPAP. As we expected,
mPAP was significantly higher in HV/SAL rats than in
LV/SAL rats at 1, 1.5, and 2 h after the start of mechanical
ventilation. The increase in mPAP was significantly attenu-
ated in the HV/TM group compared with the HV/SAL
group at 1 and 1.5 h. There were no differences in the
mPAP between the HV/TM and LV groups (Figure 3A),
suggesting that TM treatment prevented the increase in
mPAP caused by high tidal volume ventilation. Similar
results were obtained for Pp/Ps, an index of pulmonary
hypertension [25]. Pp/Ps was significantly higher in
HV/SAL rats than LV/SAL rats at 1.5 and 2 h after the
start of mechanical ventilation. The increase in Pp/Ps was
significantly attenuated in the HV/TM group comparedwith the HV/SAL group at 1, 1.5, and 2 h. There were no
differences in the Pp/Ps between the HV/TM group and
LV groups (Figure 3B). The results of mPAP and Pp/Ps
are suggestive of the effects of TM-inhibiting pulmonary
hypertension induced by hypercytokinemia due to the
lung injury created by high level of oxygen with large-tidal
volume mechanical ventilation.
Peak inspiratory airway pressure
Peak inspiratory airway pressure (PIP) was significantly
increased in the HV/SAL group and HV/TM group
compared with the LV/SAL group and LV/TM group,
respectively. There was no difference between the HV/
TM group and HV/SAL group (Figure 3C). PIP might
be insensitive to detect the effect of TM on the lung
injury created by high level of oxygen with large-tidal
volume mechanical ventilation.
Inflammatory cytokines and chemokines
To confirm that the inflammatory response is accentuated
in HV/SAL rats compared with LV/SAL rats, we measured
cytokine and chemokine mRNA levels in the lungs. IL-1α,
IL-1β, IL-6, TNFα, and MIP-2 mRNA levels in the lungs
Figure 3 Mean pulmonary artery pressure, Pp/Ps, and peak inspiratory airway pressure. (A) Mean pulmonary artery pressure (mPAP),
(B) the ratio of mean pulmonary artery pressure to mean artery pressure (Pp/Ps), (C) peak inspiratory airway pressure (PIP). (B) −0.5 h, baseline
measurement before the start of experimental tidal volumes. See Figure 2 for other abbreviations. Bars indicate mean ± SE. *P < 0.05 versus the
respective LV groups. #P < 0.05 versus the HV/SAL group. n = number of rats.
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the LV/SAL group. These increases in IL-1α, IL-1β, IL-6,
and MIP-2 mRNA levels were significantly attenuated in
the HV/TM group compared with the HV/SAL group
(Figure 4). There was no difference in the level of TNFα
mRNA between the HV/TM group and HV/SAL group.
ROCK-1
Because ROCK-1 protein level increased in the lung tissue
in mice VILI model [9], we determined ROCK-1 mRNA
and protein level in the lung tissue with and without
TM treatment. There was no change in ROCK-1 mRNA
expression among the groups (Figure 5A). ROCK-1 pro-
tein expression was significantly decreased in the HV/SAL
group and HV/TM group compared with the LV/SAL
group and LV/TM group, respectively (Figure 5B). No
difference was found between the HV/SAL and HV/TM
groups.
HMGB-1
Because TM has been shown to neutralize HMGB-1, a
mediator of inflammation and increased permeability
through activation of inducible nitric oxide synthase [16,26],
we investigated whether TM administration would reduce
HMGB-1 mRNA and protein expressions in the lung in high
tidal ventilation. Unexpectedly, HMGB-1 mRNA and proteinexpressions in the lung were significantly decreased in
the HV/SAL group and HV/TM group compared with
the LV/SAL group and LV/TM group, respectively. No
difference was found between the HV/SAL and HV/TM
groups (Figure 5C).
Discussion
The results of this study showed that high tidal volume
ventilation with 100% oxygen induced lung injury, associ-
ated with the upregulation of proinflammatory cytokine
mRNA in the injured lung. TM pretreatment attenuated
the decrease in PaO2, lung permeability, and mPAP in
VILI rats. Proinflammatory cytokine mRNA levels in the
injured lung were decreased in VILI rats treated with TM.
Ventilation with high tidal volume and 100% oxygen
significantly upregulated protein permeability measured
by EBD extravasation into the lung in rats. The lung
dry/wet weight ratio was also nonsignificantly increased
in the HV/SAL group compared with the LV/SAL group.
These results suggest that EBD extravasation is more
sensitive for detecting the increase in protein permeability
in the lung than dry/wet weight ratios in the early phase
of VILI. The EBD extravasation of LV with room air
(LV group in preliminary experiment) and LV with 100%
oxygen (LV/SAL group in main experiment) were similar.
Thus, we could not detect apparent oxygen toxicity in the
Figure 4 rhsTM attenuated the increase in cytokine and chemokine mRNA in VILI in rats. Cytokine [interleukin (IL)-1α (A), IL-1β (B), IL-6
(C), tumor necrosis factor α (TNFα) (D)] and chemokine (macrophage inflammatory protein (MIP)-2) (E) mRNA expressions in the lung tissue were
significantly higher in the HV/SAL group than in the LV/SAL group. Note significant differences between the HV/TM group and HV/SAL group for
IL-1α, IL-1β, IL-6, and MIP-2. *P < 0.05 versus the LV group. #P < 0.05 versus the HV/SAL group. n = number of rats. See Figure 2 for abbreviations.
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lung injury model was induced by combined high level of
oxygen and large tidal volume mechanical ventilation.
The results showed that TM administration prevented
VILI, as evidenced by the reduction in protein leakage,
attenuation of the decrease in arterial oxygenation in high
tidal volume ventilation, and prevention of the increase in
mPAP and Pp/Ps ratio. Although this protective effect of
rhsTM was associated with a reduction of chemokine
(MIP-2) and cytokine (IL-1α, IL-1β, and IL-6) mRNA
expression in the lungs with high volume ventilation, a
causal relationship between VILI and these mediators
remains to be determined [1]. An earlier study showed that
IL-1 receptor antagonist protects against VILI in rabbits,
suggesting that IL-1 is a candidate mediator of VILI [27].
Cytokines and chemokines
Expressions of proinflammatory cytokines (IL-1α, IL-1β,
IL-6, and TNFα) in TM-untreated lung were significantly
elevated following high volume ventilation, which confirms
that a high volume ventilation is associated with a pro-
inflammatory reaction. Since TNFα and IL-1β suppress TM
mRNA in endothelial cells [11,28], the increase in these
cytokines in the present study shows a possible lack ofTM during high volume ventilation. A lack of TM is
associated with activation of mitogen-activated kinase and
an increase in NFκB and ICAM expression [11], thereby
potentiating the inflammatory reaction. If there is a lack of
TM during high volume ventilation, TM administration
could be used as a supplementation therapy. Because TM
administration attenuates the increase in IL-6 and IL-1β
mRNA, the inflammatory response might be attenuated
by TM supplementation. Additional experiment such as
determination of TM concentration or TM staining in the
lung tissue is necessary.
ROCK-1 protein expression was reduced in rats with
high volume tidal ventilation, and TM had no effect on
ROCK-1 expression. A previous study that found that
expression of ROCK-1 in the lung was increased in VILI
mice showed that APC-mediated vascular protection
involves inhibition of ROCK-1 [9]. Upregulation of ROCK-
1 increases vascular permeability through endothelial
gap formation [29]. However, this mechanism was not
the case in the present study because ROCK-1 mRNA
expression was unchanged. Species difference and model
difference might explain the difference of ROCK-1 expres-
sion. Furthermore, TM administration might not increase
APC in the present study, because rhsTM activates
Figure 5 ROCK-1 and HMGB-1. (A) Rho-associated kinase (ROCK)-1 mRNA, (B) ROCK-1 protein expression, (C) high-mobility group box 1
(HMGB-1) mRNA, (D) HMGB-1 protein expression. For protein expression, the average intensity of LV/SAL was taken as 100%. Each sample intensity as
a percentage of the average was calculated (relative intensity). *P < 0.05 versus the respective LV group. n = number of rats. See Figure 2
for abbreviations.
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Lung tissue MIP-2 mRNA levels were significantly
reduced by TM treatment, which might delay the occur-
rence of early VILI. MIP-2, a rodent homologue of human
IL-8 [31], is a potent monocyte attractant, initiating
cellular migration and activation and inflammatory cell
recruitment.
Since TM binds to HMGB-1 and promotes its degrad-
ation and inactivation in sepsis [12,16,26], we measured
HMGB-1 mRNA and protein expressions in the lung.
Unexpectedly, HMGB-1 mRNA and protein expressions
in the lungs were reduced in rats ventilated with high
tidal volume. The decrease in HMGB-1 protein possibly
might be due to less production since the HMGB-1
mRNA level was downregulated in rats with lung injury
created by high level of oxygen with large tidal volume
mechanical ventilation. Another possibility is that HMGB-
1 protein might be released into the systemic circulation
from the lungs during the 2-h ventilation. HMGB-1 is
normally present as a nuclear protein [32] and is passively
released from damaged cells [26]. A recent study showed
that the increase in serum HMGB-1 is associated with the
concurrent decrease in tissue HMGB-1 protein expression
of the liver in rat sinusoidal obstruction syndrome [33].
Since macrophages produce HMGB-1, the decrease in the
number of macrophages might also explain the decreasein HMGB-1 protein levels in the lung tissue. An earlier
study of bronchoalveolar lavage fluid and histology
demonstrated that alveolar macrophages decreased in
the VILI model [3]. We could not detect the effect of
TM on HMGB-1 levels in the lung tissue. However, this
result does not eliminate the possibility that TM binds
plasma HMGB-1 that has been spread from the lung.
Limitations and clinical implications
The first limitation of this study is that it is observational
and not mechanistic. Although observational, this is the
first report showing that TM blocks the development of
lung injury created by high level of oxygen with large tidal
volume mechanical ventilation in an animal model.
rhsTM (Asahi Kasei Pharma, Tokyo, Japan) has been
approved in Japan since 2008 for the treatment of DIC
with hematologic malignancy or infection. Following a
phase IIb global trial [32], a subsequent phase III global
trial of rhsTM for patients with sepsis-associated coag-
ulopathy is now underway. An observational clinical
study showed improvement in respiratory dysfunction
in patients with severe sepsis, in which the therapies
included mechanical ventilation [34]. Thus, the numbers
of septic patients under both mechanical ventilation
and rhsTM administration have been increasing [35]. If
rhsTM blocks the development of VILI, this beneficial
effect would not be limited to just those patients with
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the effect of high tidal volume and 100% oxygen. The
model of VILI should be clearly different from oxygen
toxicity, although the latter exacerbates the pathology
of the former. Since our preliminary study showed diffi-
culties to induce VILI with high tidal volume ventilation
(30–40 ml/kg) in room air and VILI was induced with
100% oxygen inhalation in other studies [2,21-23], our rats
were ventilated with high tidal volume with 100% oxygen
inhalation. Two hit lung injury, i.e., high tidal volume
and 100% oxygen inhalation, induced lung injury in the
present study. In patients under mechanical ventilation,
high oxygen inhalation is relatively common. Third, in
the present study, healthy lungs were ventilated with a
tidal volume of 35 ml/kg with resultant high peak
inspiratory pressure. Although a tidal volume of 35 ml/kg
is unrealistic in the clinical setting, a moderate tidal volume
of 10–12 ml/kg in patients with ARDS might cause a
region of overdistension equivalent to that of 40 ml/kg
ventilation because of nonhomogeneity due to a mixture
of ventilated and nonventilated regions in the lung [1].
Fourth, the duration of mechanical ventilation was short,
as in other similar studies [1,3,4,9], which is different
from the clinical setting. Thus, we can only say that
even short-term high tidal ventilation can induce VILI.
Fifth, the number of animals might be small to judge the
exact effect of TM on VILI. From the ethical standpoint
of animal experiment, we saved the number of animals
to be sacrificed.Conclusions
In summary, the results of this study show that rhsTM
administration protects against the development of lung
injury in an experimental setting, which has concomitant
decrease in cytokine mRNA expression in the lung tissue
from rats with the lung injury created by high level of
oxygen with large tidal volume mechanical ventilation.
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